Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study

NCT04517526 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT

Interventions

DRUG: pemetrexed，cisplatin/carboplatin，bevacizumab，durvalumab，SBRT

Sponsor

Shanghai Cancer Hospital, China